Associations of polymorphism in several innate immunity genes with the risk of the development of chronic lymphoproliferative diseases

The complex interaction between environmental factors and human genes makes a significant contribution to the development of chronic lymphoproliferative diseases (CLPD) in individuals with mutations in various genes, including the innate immune response genes. We examined 51 patients with chronic lymphocytic leukemia (CLL) and 70 multiple myeloma (MM) patients. The control group consisted of 47 healthy persons without hematological malignancies. The patients from control group were matched for gender and age characteristics of CLPD patients. In observed persons there was determined the prevalence of genetic polymorphisms (single-nucleotide polymorphism –SNP) in the innate immune response genes including 20 genetic polymorphisms (single-nucleotide polymorphism –SNP) in 14 genes of the innate immune response. In patients with CLL haplotype AA for the TLR3 gene in -421 position was revealed to occur significantly more often than in the control group (OR: 18.56; p= 0.005). In MM patients there was noted the relation between the risk of the development of the disease and gene polymorphism for IL-10-1082, TLR2-753 and TLR3-421. There were found genetic markers for rapidly progressing forms of CLL and MM (CG + GG haplotype of the gene IL-6 and haplotypes GG + GA gene IL-17A, respectively). It is possible to assume a probable link of gene polymorphisms for IL-6, IL-10, IL-17A, TLR2 and TLR3 with the development of the CLPD and recommend these markers as early additional diagnostic and prognostic criteria.

1. Purdue M.P., Lan Q., Wang S.S., Kricker A., Menashe I., Zheng T.Z., et al. A pooled investigation of Toll-like receptor gene variants and risk of nonHodgkin lymphoma. Carcinogenesis. 2009; 30(2): 275–81.

2. Forrest M.S., Skibola C.F., Lightfoot T.J., Bracci P.M., Willett E.V., Smith M.T., et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br. J. Haematol. 2006; 134(2): 180–3.

3. Apollonio B., Ramsay A.G. Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumor microenvironment. Br. J. Haematol.2016; 172(1): 7–8.

4. Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015; 100(12): 1495–507.

5. Koehrer S., Burger J.A. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin. Adv. Hematol. Oncol. 2016; 14(1): 55–64.

6. Spina V., Martuscelli L., Rossi D. Molecular deregulation of signaling in lymphoid tumors. Eur. J. Haematol. 2015; 95(4): 257–69.

7. Verma R., Kumar L. Molecular biology of multiple myeloma. J. Hematol. Transfus. 2015; 3(1): 1035–44.

8. Gupta A., Place M., Goldstein S., Sarkar D., Zhou S., Potamousis K., et al. Single-molecule analysis reveals widespread structural variation in multiple myeloma. PNAS. 2015; 112(25): 7689–94.

9. Boyd K.D., Pawlyn C., Morgan G.J., Davies F.E. Understanding the molecular biology of myeloma and its therapeutic implications. Expert Rev. Hematol. 2012; 5(6): 603–17.

10. Vangsted A., Klausen T.W., Vogel U. Genetic mutations in multiple myeloma I: effect on risk of multiple myeloma. Eur. J. Haematol. 2012; 88(1): 8–30.

11. Rozkova D., Novotna L., Pytlik R., Hochova I., Kozak T., Bartunkova J., Spísek R. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int. J. Cancer. 2010; 126(5): 1132–43. doi: 10.1002/ijc.24832.

12. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. A new Prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198–206.

13. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975; 36(3): 842–54.

14. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/

15. National Human Genome Research Institute. Available at: https://www.genome.gov/

16. Shaffer III A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012; 30: 565–610.

17. Barlogie B., Gale R.P. Multiple myeloma and chronic lymphocytic leukemia: parallels and contrasts. Am. J. Med. 1992; 93(4): 443–50.

18. Isaza-Correa J.M., Liang Z., van den Berg A., Diepstra A. Visser L. Tolllike receptors in the pathogenesis of human B cell malignancies. J. Hematol. Oncol. 2014; 7: 57–67. doi: 10.1186/s13045-014-0057-5.

19. Sá K.S., Pires-Neto Ode S., Santana B.B., Gomes S.T., Amoras Eda S., Conde S.R., et al. Toll-like receptor 3 gene polymorphisms are not associated with the risk of hepatitis B and hepatitis C virus infection. Rev. Soc. Bras. Med. Trop. 2015; 48(2): 136–42. doi: 10.1590/0037-8682-0008-2015.

20. Mutlu P., Yalcin S., Elci P., Yildirim M., Cetin A.T., Avcu F. Association of -174G/C interleukin-6 gene polymorphism with the risk of chronic lymphocytic, chronic myelogenous and acute myelogenous leukemias in Turkish patients. J. BUON. 2014; 19(3): 787–91.

21. Tian G., Mi J., Wei X., Zhao D., Qiao L., Yang C., et al. Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci. Rep. 2015; 5: 11394. doi: 10.1038/srep11394.

22. Yakupova E.V., Grinchuk O.V., Kalimullina D.Kh., Bakirov B.A., Galimova R.R., Makarova O.V., et al. Molecular genetic analysis of the interleukin 6 and tumor necrosis factor α gene polymorphisms in multiple myeloma. Mol. Biol. 2003; 37(3): 358–61.

23. Ennas M.G., Moore P.S., Zucca M., Angelucci E., Cabras M.G., Melis M., et al. Interleukin-IB (IL-IB) and interleukin-6 (IL-6) gene polymorphisms are associated with risk of chronic lymphocytic leukemia. Hematol. Oncol. 2008; 26(2): 98–103.

24. Heiden L., ed. Toll-like receptors. Novus Biologicals and Innate Immunity: the story of Toll’d. Handbook and Overview. Updated edition. USA: Novus Biologicals: 2014. http://images.novusbio.com/design/TLRHandbookNovus011514.pdf

25. Nazarova E.L., Shardakov V.I., Demyanova V.T., Zagoskina T.P., Zotina E.N.The diagnostic of defects of inborn immunity under B-cell tumors of lymphatic system. Clinical laboratory diagnostics. Russian Journal (Klinicheskaya laboratornaya diagnostika). 2014; 59(11): 39–42. (in Russian)

26. Pehlivan M., Sahin H.H., Pehlivan S., Ozdilli K., Kaynar L., Oguz F.S., et al. Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-b1, IFN-g, and TNF-a genes in chronic phase chronic myeloid leukemia. Genet. Test. Mol. Biomarkers. 2014; 18(6): 403–9.

27. Domingo-Domènech E., Benavente Y., González-Barca E., Montalban C., Gumà J., Bosch R., et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the urvival of patients with lymphoid neoplasms. Haematologica. 2007; 92(11): 1475–81.

28. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 2007: 137(1, Suppl.): S194–9.

29. Zheng C., Huang D., Liu L., Wu R., Bergenbrant Glas S., Osterborg A., et al. Interleukin-10 gene promoter polymorphism in multiple myeloma. Int. J. Cancer. 2001; 95(3): 184–8.

30. Mazur G., Bogunia-Kubik K., Wróbel T., Karabon L., Polak M., Kuliczkowski K., et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol. Lett. 2005; 96(2): 241–6.

31. Rudzianskiene M., Inciura A., Juozaityte E., Gerbutavicius R., Siomoliuniene R., Ugenskiene R., et al. The role of single nucleotide polymorphism of IL-6 and IL-10 cytokine on pain severity and pain relief after radiotherapy in multiple myeloma patients with painful bone destructions. Genetika. 2014; 46(2): 455–69.

32. Lech-Maranda E., Młynarski W., Grzybowska-Izydorczyk O., Borowiec M., Pastorczak A., Cebula-Obrzut B., et al. Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2013; 52(3): 287–96.

33. Resende P.G., Correia-Silva Jde F., Silva T.A., Salomão U.E., Marques--Silva L., Vieira E.L., et al. IL-17 genetic and immunophenotypic evaluation in chronic graft-versus-host disease. Mediators Inflamm. 2014; 2014: 571231. doi: 10.1155/2014/571231.